Galaxy Surfactants (NSE: GALAXYSURF) Q3 FY26 results signal portfolio resilience as specialty growth offsets global surfactant pressures
Natural Capsules (NSE: NATCAPSUQ) Q3 FY26 results signal operational recovery after regulatory shock, but fermentation execution risk still looms
Read More 5 minute read Pharma Industry News Glenmark Pharmaceuticals balances modest Q1 FY26 growth with innovation drive, global partnerships and robust pipeline ambitions Glenmark’s Q1 FY26 results reveal modest growth but highlight strong specialty launches, AbbVie licensing deal, and a robust innovation pipeline. byPallavi MadhirajuAugust 18, 2025